ArticleOpen forum infectious diseases2025
Incidence and Clinical Outcomes of Multiple Viral Infections After Allogeneic Hematopoietic Cell Transplantation.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study.Bone marrow transplantation · 2026Article
- Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recipients of allogeneic hematopoietic cell transplantation (alloHCT) are at risk of multiple viral infections. However, our knowledge about the clinical impact of viruses following alloHCT is predominantly focused on outcomes of a single viral infection such as cytomegalovirus (CMV). This retrospective cohort study aimed to evaluate the incidence, risk factors, and clinical outcomes of multiple viral infections in the first year following alloHCT. Methods: All microbiologically confirmed viral infection of CMV, Epstein-Barr virus (EBV), BK polyomavirus (BKV), varicella zoster virus, human herpesvirus 6, herpes simplex virus, and various respiratory viruses were reviewed up to 12 months post-alloHCT. Results: Among 430 alloHCT recipients, 744 viral infections were observed within the first year posttransplantation, predominantly CMV (55%), followed by EBV (51%) and BKV (21%). Eighty-five percent of patients had at least 1 viral infection, of which 34% had 2 and 24% had ≥3 viruses. Independent risk factors of multiple viral infections included CMV serostatus (R Conclusions: Multiple viral infections were frequently observed, with a significant impact on morbidity and mortality following alloHCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.